gasmas tab tablet
les laboratoires vachon inc. - aluminum hydroxide-magnesium carbonate-co dried gel; magnesium hydroxide; dimethicone - tablet - 300mg; 100mg; 25mg - aluminum hydroxide-magnesium carbonate-co dried gel 300mg; magnesium hydroxide 100mg; dimethicone 25mg - antacids and adsorbents
tyrosyl capsule
les laboratoires vachon inc. - vitamin a; vitamin d; calcium (calcium phosphate (dibasic)); phosphorus (calcium phosphate (dibasic)) - capsule - 2500unit; 133unit; 170mg; 129mg - vitamin a 2500unit; vitamin d 133unit; calcium (calcium phosphate (dibasic)) 170mg; phosphorus (calcium phosphate (dibasic)) 129mg - vitamins & minerals
phenobile tablet
les laboratoires vachon inc. - sennosides (calcium sennosides a & b); cascara sagrada - tablet - 12mg; 50mg - sennosides (calcium sennosides a & b) 12mg; cascara sagrada 50mg - cathartics and laxatives
cholestagel
cheplapharm arzneimittel gmbh - colesevelam (as hydrochloride) - hypercholesterolemia - lipid modifying agents - cholestagel co-administered with a 3-hydroxy-3-methyl-glutaryl-coenzyme-a (hmg-coa)-reductase inhibitor (statin) is indicated as adjunctive therapy to diet to provide an additive reduction in low-density-lipoprotein-cholesterol (ldl-c) levels in adult patients with primary hypercholesterolaemia who are not adequately controlled with a statin alone.cholestagel as monotherapy is indicated as adjunctive therapy to diet for reduction of elevated total cholesterol and ldl-c in adult patients with primary hypercholesterolaemia, in whom a statin is considered inappropriate or is not well tolerated.cholestagel can also be used in combination with ezetimibe, with or without a statin, in adult patients with primary hypercholesterolaemia, including patients with familial hypercholesterolaemia (see section 5.1).
zurampic lesinurad tablet film coated
astrazeneca pharmaceuticals lp - lesinurad (unii: 09erp08i3w) (lesinurad - unii:09erp08i3w) - lesinurad 200 mg
emend 80 mg capsules
merck sharp & dohme israel ltd - aprepitant - capsules - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
emend 80 mg capsules
merck sharp & dohme israel ltd - aprepitant - capsules - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
emend 80 mg capsules
merck sharp & dohme (israel - 1996) company ltd, israel - aprepitant - capsules - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
emend 125 mg capsules
merck sharp & dohme israel ltd - aprepitant - capsules - aprepitant 125 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
emend 125 mg capsules
merck sharp & dohme (israel - 1996) company ltd, israel - aprepitant - capsules - aprepitant 125 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.